Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Vanguard Health Care ETF

311.07
-0.6550-0.21%
Volume:86.42K
Turnover:26.91M
Market Cap:18.72B
PE:33.77
High:313.00
Open:313.00
Low:310.31
Close:311.72
52wk High:330.75
52wk Low:263.00
Shares:60.18M
Float Shares:60.18M
Volume Ratio:0.65
T/O Rate:0.14%
Dividend:4.61
Dividend Rate:1.48%
EPS(TTM):9.21
EPS(LYR):41.51
ROE:3.75%
ROA:0.89%
PB:0.95
PE(LYR):7.49

Loading ...

OverviewCompanyNewsFilings

Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients taking Foundayo

TIPRANKS
·
Sep 22

Top Midday Stories: Paramount Skydance Settles With US States to Pave Way for Warner Bros. Deal; Anthropic Now Eyeing November IPO

MT Newswires Live
·
Sep 21

Novo Nordisk Says New Obesity Drug Outperformed Lilly's Zepbound in Phase 3 Trial

Dow Jones
·
Sep 21

J&J says Caplyta Phase 3 study in bipolar I met primary endpoint

TIPRANKS
·
Sep 21

Novo Stock (NVO) Sinks Despite Beating Eli Lilly in New CagriSema Obesity Trial

TIPRANKS
·
Sep 21

Pharma Sector Doubles Down on AI to Slash Costs, Timelines

Reuters
·
Sep 21

AbbVie, Iambic Sign Multiyear Drug Discovery Deal

MT Newswires Live
·
Sep 21

AbbVie Partners with Iambic to Accelerate AI-Driven Small-Molecule Drug Discovery

Reuters
·
Sep 21

Johnson & Johnson Says Phase 3 Trial Shows Caplyta Cuts Bipolar I Mania Symptoms by Week 3

Reuters
·
Sep 21

Abbvie and Iambic Announce Collaboration to Accelerate AI-Driven Drug Discovery

THOMSON REUTERS
·
Sep 21

Abbvie - Iambic to Receive Upfront Payment, Milestone Payments, and Tiered Royalties from Collaboration

THOMSON REUTERS
·
Sep 21

Abbvie - Partnership to Accelerate Small Molecule Drug Discovery in Immunology, Neuroscience, Oncology

THOMSON REUTERS
·
Sep 21

J&J - Caplyta Demonstrates Statistically Significant Rapid Reduction in Manic Symptoms at Week 3

THOMSON REUTERS
·
Sep 21

Caplyta® (Lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Pivotal Phase 3 Study

THOMSON REUTERS
·
Sep 21

J&J - Caplyta Well-Tolerated; Dry Mouth and Nausea Most Common Adverse Events

THOMSON REUTERS
·
Sep 21

Adarx Pharmaceuticals: IPO Price Expected Between $15 and $17 Per Share

Reuters
·
Sep 21

Oura Files for Initial Public Offering on Nasdaq

MT Newswires Live
·
Sep 21

LIVE Markets-Big Beauty Faces Growing Threat from AI, Smaller Rivals

Reuters
·
Sep 21

ADARx Pharmaceuticals to Sell 21.9 Million Shares at $15-$17 Each in IPO

Dow Jones
·
Sep 21

Smart Ring Maker Oura Eyes $15.6 Billion IPO Valuation in Fall Listings Demand Test

Reuters
·
Sep 21
More